| Literature DB >> 35626131 |
Maria Mulet1, Rubén Osuna-Gómez1, Carlos Zamora1, José M Porcel2, Juan C Nieto1, Lídia Perea1, Virginia Pajares3, Ana M Muñoz-Fernandez3, Nuria Calvo4, Maria Alba Sorolla5, Silvia Vidal1.
Abstract
Malignant pleural effusion (MPE) is a common severe complication of advanced lung adenocarcinoma (LAC). Neutrophils, an essential component of tumor infiltrates, contribute to tumor progression and their counts in MPE have been associated with worse outcome in LAC. This study aimed to evaluate phenotypical and functional changes of neutrophils induced by MPE to determine the influence of MPE immunomodulatory factors in neutrophil response and to find a possible association between neutrophil functions and clinical outcomes. Pleural fluid samples were collected from 47 LAC and 25 heart failure (HF) patients. We measured neutrophil degranulation products by ELISA, oxidative burst capacity and apoptosis by flow cytometry, and NETosis by fluorescence. The concentration of degranulation products was higher in MPE-LAC than in PE-HF. Functionally, neutrophils cultured with MPE-LAC had enhanced survival and neutrophil extracellular trap (NET) formation but had reduced oxidative burst capacity. In MPE, NETosis was positively associated with MMP-9, P-selectin, and sPD-L1 and clinically related to a worse outcome. This is the first study associating NETs with a worse outcome in MPE. Neutrophils likely contribute to tumor progression through the release of NETs, suggesting that they are a potential therapeutic target in LAC.Entities:
Keywords: NETosis; lung adenocarcinoma; malignant pleural fluid; neutrophils
Year: 2022 PMID: 35626131 PMCID: PMC9139419 DOI: 10.3390/cancers14102529
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Demographic, clinical, and molecular parameters of the patients with pleural effusions included in the study.
| Patients Characteristics | HF | LAC | |
|---|---|---|---|
| Number of patients | 25 | 47 | |
| Male/female | 17/8 | 36/11 | n.s. |
| Median age (range), years | 85 (81–88) | 69 (62–75) | <0.001 |
| Median (IQR) survival time from diagnosis, days | NA | 203.5 (69.3–527.8) | |
| EGFR mutations | NA | 11/47 | |
| ALK mutations | NA | 4/47 | |
|
| |||
| 0 | NA | 12/47 | |
| 1 | NA | 8/47 | |
| 2 | NA | 5/47 | |
| 3 | NA | 10/47 | |
| 4 | NA | 5/47 | |
| NA | NA | 7/47 | |
|
| |||
| Glucose (mg/mL) | 125.5 (102.8–154) | 99 (81.56–123.8) | 0.026 |
| Lactate dehydrogenase (U/L) | 163.5 (138.8–211.3) | 755 (449–1253) | <0.001 |
| C-reactive protein (mg/L) | 3.8 (2.3–10.9) | 11.2 (6.4–34.6) | 0.004 |
| Adenosine deaminase (U/L) | 4.3 (3.2–7.8) | 7.4 (5.1–10.5) | n.s. |
| Total protein (g/dL) | 2.6 (1.8–3) | 4.8 (4–5.7) | <0.001 |
| pH | 7.5 ± 0.02 | 7.4 ± 0.02 | 0.001 |
|
| |||
| Radiotherapy | NA | 5/47 | |
| Chemotherapy | NA | 17/47 | |
| Immunotherapy | NA | 10/47 | |
| ALK inhibitors | NA | 2/47 | |
| EGFR inhibitors | NA | 5/47 | |
| Her2 inhibitors | NA | 2/47 | |
| Untreated or palliative care | NA | 6/47 | |
|
| |||
| PF4 (pg/mL) | 3281 (2125–4593) | 8282 (4107–14,605) | <0.001 |
| VEGF (ng/mL) | 119.3 (1–455.3) | 2377 (313.3–3598) | 0.001 |
| P-selectin (pg/mL) | 4440 ± 323.7 | 11,484 ± 1260 | 0.001 |
| TGF-β (pg/mL) | 11,572 (9320–15,950) | 16,838 (8662–28,772) | 0.04 |
| CD40L (pg/mL) | 2.1 (1–56.2) | 26.2 (2.1–157.1) | 0.07 |
| PD-L1 (pg/mL) | 40.3 (32.5–73.6) | 96.4 (76.4–132.6) | <0.001 |
ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; HF, heart failure; LAC, lung adenocarcinoma; NA, not applicable; n.s., non-significant; PF4, platelet factor 4, CD40L, soluble CD40L; PD-L1, soluble programmed death-ligand 1; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor. Nonparametric Mann–Whitney test was used for all comparisons except for pH and P-selectin, which were compared by t-test.
Phenotype of neutrophils present in pleural effusions from HF and LAC.
| PE-HF | MPE-LAC | ||
|---|---|---|---|
| Neutrophils (cell/mL) | 24,000 (4967–106,120) | 21,170 (1491–140,580) | n.s.1 |
| Neutrophil phenotype | |||
| CD15 expression (MFI) | 48.6 ± 6.5 | 55.9 ± 10.9 | n.s. 2 |
| CD16 expression (MFI) | 21.8 ± 3.8 | 26.2 ± 3.6 | n.s. 2 |
| CD66b expression (MFI) | 19.2 (14.2–25.3) | 22.9 (14.7–26.8) | n.s. 1 |
| S100A8/9+ neutrophils (%) | 48.5 ± 7.4 | 31.4 ± 3.8 | 0.09 2 |
| CD200R+ neutrophils (%) | 5.1 ± 1.9 | 4.3 ± 0.6 | n.s. 2 |
MFI: mean fluorescence intensity. 1 Nonparametric Mann–Whitney test; 2 t-test.
Figure 1Pleural fluid concentrations of soluble neutrophil-related molecules. Levels of (A) myeloperoxidase (MPO; ng/mL), (B) lactoferrin (ng/mL), (C) matrix metalloproteinase-9 (MMP-9; pg/mL), (D) IL-8 (pg/mL), and (F) nitrate (µmol/L) in pleural effusions from heart failure (PE-HF) (n = 25) and lung adenocarcinoma (MPE-LAC) (n = 47) cell-free pleural fluids determined by the corresponding ELISAs. (F) Pleural extracellular DNA was measured in PE-HF (n = 17) and MPE-LAC (n = 25) by fluorescence intensity and expressed as relative fluorescence units (RFUs). The unpaired T-test (E) and the Mann–Whitney test (A–D), (F) were used for statistical analyses. P-values are shown in the graphs.
Figure 2Effect of cell-free pleural fluid on neutrophil viability, NETosis, and oxidative burst. Healthy neutrophils were cultured in the presence of pleural fluids (25% of volume). Viability and oxidative burst capacity were determined by flow cytometry and NET formation was measured by fluorescence. (A) The viability of neutrophils in the presence of pleural effusions from heart failure (PE-HF) (n = 20) and lung adenocarcinoma (MPE-LAC) (n = 26). Data were expressed as ratios calculated by dividing PE-HF or MPE-LAC values by their respective medium values. (B) Representative flow cytometry plots of apoptosis assay of neutrophils cultured with cf-PE-HF and cf-MPE-LAC. Quadrants are V for viable cells, EA for early apoptosis, and LA for late apoptotic cells. (C,D) Capacity of PE-HF (n = 20) and MPE-LAC (n = 26) to trigger NET formation and oxidative burst, respectively, under PMA-stimulation conditions. Data were expressed as ratios calculated by dividing PE-HF or MPE-LAC values by their respective control medium values. (E) Representative flow cytometry histograms of ROS production of neutrophils cultured in the presence of cf-PE-HF (grey line) or MPE-LAC (black line). The Mann–Whitney test was used for statistical analyses. P-values are shown in the graphs.
Figure 3Correlation matrixes between neutrophil functions and platelet and neutrophil-derived factors in cf-PFs. Correlation matrices showing the association between neutrophil- and platelet- derived factors and neutrophils functions in (A) PE-HF and (B) MPE-LAC. The strength and direction of the correlations are indicated by the circle size and color. The statistical significance was represented by (*) p < 0.05, (**) p < 0.01, and (***) p < 0.001. Spearman correlations were established (C) between NETosis and the levels of MPO, MMP-9, and PF4 in cf-PE-HF and (D) between NETosis and the levels of lactoferrin and sPD-L1 in cf-MPE-LAC. The Pearson correlation was used for the correlation between NETosis and P-selectin.
Figure 4Correlation between paraclinical parameters and the pleural concentration of neutrophil-derived products in LAC patients with MPE. Positive correlation between (A–C) LDH (U/L) or (D–F) CRP (mg/L) and levels of MPO (ng/mL), lactoferrin (ng/mL) and MMP-9 (pg/mL). R and p values were calculated using Spearman’s correlation coefficient.
Figure 5Association between pleural neutrophil-related factors and functions and LAC patient survival. Correlations between the percentage of tumor cells and pleural levels of (A) MMP-9 (pg/mL) and (B) lactoferrin (ng/mL). (C) Spearman positive correlation between pleural lactoferrin levels (ng/mL) and survival days after MPE diagnosis in LAC patients. (D) Pearson negative correlation between PMA-induced cf-PE NETosis and survival days after MPE diagnosis. (E) Comparison of 180-day survival of LAC patients based on the ability of their pleural fluids to induce NETosis. Correlation coefficients and p-values are presented in the graphs. The unpaired t-test was used for the statistical analysis of 180-day survival. NETosis-related data are expressed as ratios calculated by dividing LAC values by their respective medium values.